Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility; Sentry will label, package and ship the clinical supplies from its site in Indianapolis, Indiana. The collaboration will help streamline the path of study drugs from filling lab to clinic while safeguarding product integrity.
Peter Soelkner, managing director of Vetter, said: “Our partnership with Sentry affirms our mutual commitment to helping clients get high-quality products to market quickly and efficiently. It also affirms Vetter’s commitment to the North American market.
“The Chicago facility, which focuses on preclinical to Phase II projects, is Vetter’s first outside of Germany and is an expansion of Vetter Development Service. It will be operational at the beginning of Q4 2010.”
Jennifer Marcum, CEO of Sentry, said: “We’re proud to partner with Vetter. In addition, we’re both privately held companies with central US locations allowing rapid response to industry needs and accessibility to clients across North America.”